相关实验视频

Updated: May 14, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

彻底Fare心房压控制器装置在高级肺动脉高血压中创建可控的右至左心房间间的分流 - 一项试点研究

Bojja Venkata Satya Roopesh¹, Girija Haritha², S V Kishore³

¹Department of Pediatric Cardiology, Institute of Cardio Vascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India.

Annals of pediatric cardiology

|May 12, 2025

概括

ThoroughFare心房压控制器是一种用于肺动脉高血压 (PAH) 的新设备,该设备在患有严重PAH的患者中显示出可行性和安全性. 短期随访表明症状改善和设备通透性.

科学领域:

心脏病学心脏病学
医疗器械医疗器械
肺高血压是什么意思肺高血压

背景情况:

心房流量调节器在肺动脉高血压 (PAH) 患有昏迷或心力衰竭的患者中管理症状.
ThoroughFare 心房压力控制器是一种新的设备,具有电缆螺丝释放机制和低调.

研究的目的:

评估ThoroughFare心房压控制器在患有严重PAH的患者中的可行性和安全性.
评估设备植入后的短期结果.

主要方法:

一项涉及15名症状PAH患者 (5-39岁) 的多机构研究,这些患者接受了该设备.
植入经过穿越性穿刺后使用8毫米窗口直径装置和12F进行了植入.
患者已经接受了至少2年的双重肺血管扩展剂药物治疗.

主要成果:

在所有患者中,植入手术在没有并发症的情况下成功完成.
在8个月的中位数随访期间观察到症状改善.
所有患者都证实了设备的通透性,其中有一例死于心肺移植.

结论:

对于严重的PAH患者来说,ThoroughFare心房压控制器植入是可行的和安全的.
需要对更大的队列进行进一步的长期研究,以确认功能益处.

关键词:

耳前流量调节器耳前流量调节器在心房隔膜造影中,心房的隔膜造影.肺高血压是一种肺高血压.右心室的功能障碍综合症综合症是什么

更多相关视频

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...